The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVR C5252 (Primary)
Indications Glioblastoma; Glioma
Focus Adverse reactions; Therapeutic Use
Acronyms PuMP

Most Recent Events

31 Jul 2024 Status changed from not yet recruiting to recruiting.
20 Mar 2024 Planned initiation date changed from 1 Feb 2024 to 1 May 2024.
13 Dec 2023 Planned initiation date changed from 1 Dec 2023 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com